跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 1,070 条关于
“Suzhou Zelgen Biopharmaceuticals”
全部
1,070
临床试验
107
药物
347
机构
181
资讯
435
去年
Ankylosing Spondylitis Pipeline Shows Robust Growth with 20+ Therapies in Development
去年
Spinal Cord Injury and Ankylosing Spondylitis: Advances in Clinical Trials and Therapies
去年
Gecacitinib Shows Superior Efficacy and Safety Over Hydroxyurea in Myelofibrosis Patients
9个月前
Novel Astatine-211 Targeted Alpha Therapy Shows Promise for Radioactive Iodine-Refractory Thyroid Cancer
去年
Thyroid Cancer Pipeline Shows Robust Growth with 50+ Companies Developing Novel Therapies
去年
China Adds 90 Innovative Drugs to National Reimbursement List, Boosting Access to Cancer and Rare Disease Treatments
去年
Gastric Cancer Pipeline Shows Robust Growth with 220+ Therapies in Development Across 200+ Companies
8个月前
AbbVie Secures $1.1B Deal for Zelgen's DLL3-Targeting Cancer Therapy
5个月前
WuXi Biologics' Suzhou Biosafety Testing Center Earns Fourth EMA GMP Certification, Enabling 19 Biologics for EU Market
去年
Provectus Biopharmaceuticals Launches VisiRose for Ophthalmic Therapies
第 1 页，共 44 页
上一页
下一页
